Get your headlines, email, quotes and more — all in one place.
"I think it’s happening." View Entire Post ›
It's the most wonderful smelling time of the year. View Entire Post ›
Make Beethoven proud! View Entire Post ›
Coronavirus testing numbers are likely to be erratic over the next week or so, experts said Friday, as fewer people get tested during the Thanksgiving holiday weekend.'Don't misinterpret the numbers' »
Full Year 2020 Benchmark Holdings PLC Earnings Call
Full Year 2020 Benchmark Holdings PLC Earnings Call
It’s a bearish start to the day for the majors. Failure to move back through early highs would bring support levels into play.
It’s a bearish start to the day for the majors. Failure to move back through early highs would bring support levels into play.
Mental health pros share the most meaningful "gifts" to set yourself up for personal growth in the year ahead.
Mental health pros share the most meaningful "gifts" to set yourself up for personal growth in the year ahead.
AstraZeneca is working with regulators to investigate a lower dosage of its experimental COVID-19 vaccine that performed better than a full dosage. That’s according to a spokesman for the company, who made the statement after its CEO was quoted as saying an additional global trial was likely - instead of adding the trial to an ongoing U.S. process. Asked about a Bloomberg report which quoted CEO Pascal Soriot, an AstraZeneca spokesman said : "As we communicated earlier this week, there is strong merit in continuing to further investigate the half-dose/full dose regimen." News of a likely additional trial comes as AstraZeneca faces questions about its success rate that some experts say could harm its chances of getting speedy U.S. and EU approval. Several scientists have cast doubts on results released Monday showing the experimental vaccine was 90% effective in a sub-group of trial participants who, by error initially, received a half dose followed by a full dose. AstraZeneca told Reuters earlier on Thursday that administering of the half dose had been reviewed and approved by independent monitors and the UK regulator. Clearance from the U.S. Food and Drug Administration may take longer though because the agency is unlikely to approve the vaccine based on studies carried out elsewhere, according to Soriot, especially given the questions over the results.
AstraZeneca is working with regulators to investigate a lower dosage of its experimental COVID-19 vaccine that performed better than a full dosage. That’s according to a spokesman for the company, who made the statement after its CEO was quoted as saying an additional global trial was likely - instead of adding the trial to an ongoing U.S. process. Asked about a Bloomberg report which quoted CEO Pascal Soriot, an AstraZeneca spokesman said : "As we communicated earlier this week, there is strong merit in continuing to further investigate the half-dose/full dose regimen." News of a likely additional trial comes as AstraZeneca faces questions about its success rate that some experts say could harm its chances of getting speedy U.S. and EU approval. Several scientists have cast doubts on results released Monday showing the experimental vaccine was 90% effective in a sub-group of trial participants who, by error initially, received a half dose followed by a full dose. AstraZeneca told Reuters earlier on Thursday that administering of the half dose had been reviewed and approved by independent monitors and the UK regulator. Clearance from the U.S. Food and Drug Administration may take longer though because the agency is unlikely to approve the vaccine based on studies carried out elsewhere, according to Soriot, especially given the questions over the results.
And they're selling quickly!
And they're selling quickly!
USD/CAD managed to get below the support at 1.3000 and is testing the next support level at 1.2985.
USD/CAD managed to get below the support at 1.3000 and is testing the next support level at 1.2985.
* U.S. holiday gives few trading cues to stocks * Real stabilizing, Brazil central bank head says * Petrobras shares down after firm cuts spending plan By Ambar Warrick Nov 26 (Reuters) - Brazil's real ticked higher on Thursday after encouraging comments from the central bank president, while most other Latin American units edged lower as optimism over a coronavirus vaccine waned. The real added 0.3% after central bank president Roberto Campos Neto said the currency looked to have stopped weakening and was now stabilizing, indicating that upward pressure on inflation this year will ease. The country reported its smallest monthly primary deficit since the advent of the pandemic, indicating a recovery in Latin America's largest economy was underway.
* U.S. holiday gives few trading cues to stocks * Real stabilizing, Brazil central bank head says * Petrobras shares down after firm cuts spending plan By Ambar Warrick Nov 26 (Reuters) - Brazil's real ticked higher on Thursday after encouraging comments from the central bank president, while most other Latin American units edged lower as optimism over a coronavirus vaccine waned. The real added 0.3% after central bank president Roberto Campos Neto said the currency looked to have stopped weakening and was now stabilizing, indicating that upward pressure on inflation this year will ease. The country reported its smallest monthly primary deficit since the advent of the pandemic, indicating a recovery in Latin America's largest economy was underway.
The Duchess of Cambridge is unveiling the results of her under-fives project: 'Homelessness, addiction, poor mental health are often grounded in a difficult childhood'
The Duchess of Cambridge is unveiling the results of her under-fives project: 'Homelessness, addiction, poor mental health are often grounded in a difficult childhood'
| Symbol | Price | Change | % Chg |
|---|---|---|---|
| ^GSPC | 3,638.35 | 8.70 | 0.24% |
| ^DJI | 29,910.37 | 37.90 | 0.13% |
| ^IXIC | 12,205.85 | 111.44 | 0.92% |
| ^RUT | 1,855.27 | 10.25 | 0.56% |
| CL=F | 45.53 | -0.18 | -0.39% |
| GC=F | 1,781.90 | -23.60 | -1.31% |
| SI=F | 22.64 | -0.81 | -3.44% |
| EURUSD=X | 1.20 | 0.01 | 0.48% |
| ^TNX | 0.84 | -0.04 | -4.10% |
| GBPUSD=X | 1.33 | -0.00 | -0.32% |
| JPY=X | 104.05 | -0.20 | -0.19% |
| BTC-USD | 16,980.55 | -204.80 | -1.19% |
| ^CMC200 | 333.27 | -4.23 | -1.25% |
| ^FTSE | 6,367.58 | 4.65 | 0.07% |
| ^N225 | 26,644.71 | 107.40 | 0.40% |
According to a report from the Financial Times, Facebook-backed cryptocurrency Libra could launch in
Ride-hailing firms such as Ola and Uber can only draw a fee of up to 20% on ride fares in India, New Delhi
Hacker houses are making a comeback for entrepreneurs as remote work drags on. While founders are adapting
As the coronavirus pandemic surges across the country, hospitals are facing a crisis-level shortage of beds
The incoming administration aims to tackle child care, elder care, preschool and more in one ambitious aid
The coronavirus is not a shape shifter like the flu virus, but it could become vaccine resistant over time.
